Physician profile
Gwenesta B Melton
NPI 1780697326
$410,415.46
in general payments reported to CMS, 2019-2025
30 companies · $40K in 2025
The $40K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177K · 2020: $39K · 2021: $48K · 2022: $55K · 2023: $19K · 2024: $32K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Consulting Fee: $27K · Travel and Lodging: $9,174 · Food and Beverage: $6,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,906.00 |
| Consulting Fee | $27,087.50 |
| Travel and Lodging | $9,174.36 |
| Food and Beverage | $6,226.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100,910.56 | 2019-2023 | |
| Abbvie INC. | $83,238.79 | 2019-2025 | |
| Genzyme Corporation | $79,565.26 | 2019-2025 | |
| Ucb, INC. | $50,592.76 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $25,069.07 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $21,534.82 | 2019-2025 | Cosentyx |
| Gilead Sciences, INC. | $15,214.85 | 2019-2020 | |
| Janssen Biotech, INC. | $8,909.64 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $8,712.37 | 2019-2020 | |
| Lilly USA, LLC | $5,620.24 | 2019-2024 | Taltz, Olumiant |
| Sobi, INC | $4,546.67 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $3,236.67 | 2021-2023 | Lupkynis |
| Eli Lilly and Company | $1,397.87 | 2024 | Taltz |
| Glaxosmithkline, LLC. | $481.30 | 2019-2023 | Benlysta |
| Janssen Scientific Affairs, LLC | $330.79 | 2019-2025 | Tremfya |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $235.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $206.42 | 2019-2021 | |
| Medexus Pharma, INC. | $194.95 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $145.68 | 2021-2023 | Saphnelo |
| Horizon Therapeutics Plc | $43.71 | 2019 | |
| Mallinckrodt Enterprises LLC | $42.45 | 2019 | |
| Celgene Corporation | $36.23 | 2019 | |
| Merck Sharp & Dohme LLC | $29.24 | 2019-2020 | |
| Genentech USA, INC. | $27.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.14 | 2019 | |
| Antares Pharma, INC. | $18.31 | 2019 | |
| Hikma Pharmaceuticals USA | $14.98 | 2020 | |
| Forte Bio-Pharma LLC | $14.70 | 2019 | |
| Assertio Therapeutics, INC. | $13.17 | 2019 | |
| Biodelivery Sciences International, INC. | $12.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gwenesta Melton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.